An amyloidosis diagnosis can take upwards of 2 years.
Initial symptoms often are nondescript, and irreversible organ damage frequently occurs before disease confirmation.
“About two-thirds of patients will see three-plus providers before the diagnosis is actually made,” Hira Shaikh, MBBS, clinical assistant professor of internal medicine in the division of hematology, oncology, and blood and marrow transplantation at Carver College of Medicine at The University of Iowa, told Healio.
This prompted American Society of Hematology to come up with its first guideline for diagnosis of light chain

Once-daily orforglipron induced greater reductions in HbA1c and body weight than once-daily oral semaglutide for adults with type 2 diabetes, according to data from the ACHIEVE-3 trial published in The Lancet.
In a randomized, phase 3, open-label trial comparing two oral GLP-1 receptor agonists, a greater percentage of adults receiving orforglipron 12 mg or 36 mg (Eli Lilly) were able to achieve an HbA1c of less than 7%, 6.5% and 5.7% vs. those receiving 7 mg or 14 mg of oral semaglutide (Ozempic pill, formerly known as Rybelsus, Novo Nordisk). Additionally, orforglipron was tied to

A research group at the Universidade Federal do Rio de Janeiro has advanced polylaminin, a laminin-based biomaterial, from preclinical investigation to early human testing in spinal cord injury.
Polylaminin is a polymerized form of laminin, an extracellular matrix glycoprotein known to support neuronal adhesion, axonal growth and synaptic organization during neurodevelopment.
Foundational preclinical work has demonstrated that polymerized laminin promotes axonal regeneration and functional recovery in rodent models of spinal cord injury, providing biological plausibility for translational

Use of GLP-1 agonists after anterior cervical discectomy and fusion may reduce the rates of pseudoarthrosis, dysphagia, revision surgery, sepsis and overall hospitalizations, according to results.
“On preliminary review, [GLP-1 agonists] look to be beneficial in multiple aspects of surgical healing, including the healing of bone,” Nitin N. Bhatia, MD, professor and chair of orthopedic surgery at University of California, Irvine, told Healio.
Using the TriNetX database, Bhatia, along with Manaav Mehta, BS, and colleagues, retrospectively reviewed data from patients undergoing

According to Mental Health America, bipolar disorder affects an estimated 4.4% of the United States population.
Black patients and patients from other underrepresented groups in the U.S. often face stigma and barriers to receiving adequate medication and treatment.
To recognize Black History Month in February and Bipolar Awareness Day in late March, Healio spoke with Kevin N. Williams, MS, MPAS, PA-C, CEO and lead clinician at OnPoint Behavioral Health in Tampa, Florida. Here, he provides insight and perspective on how those with bipolar as well as their support systems can weather both

Retractions in rheumatology clinical trial literature have increased “substantially” over the past 35 years, largely due to misconduct, according to findings published in Arthritis Care & Research.
“Although still relatively low, the rate of retraction in medicine has risen in recent years, with the frequency and causes of retraction varying considerably across medical fields,” Anna Maria Vettori, an international baccalaureate student at the St. Louis School in Milan, Italy, and Michelle Iudici, MD, PhD, MPH, of the division of rheumatology at Geneva University